Autosomal Dominant Polycystic Kidney Disease
Tolvaptan may slow eGFR decline in patients with autosomal dominant PKD
Routine use of tolvaptan in clinical practice may slow eGFR decline for patients with autosomal dominant polycystic kidney disease compared with historical controls, data show.
Race may affect waitlisting, allograft and transplant outcomes in autosomal dominant PKD
Race may play a role in the waitlist experience, allograft quality and transplant outcomes of patients with autosomal dominant polycystic kidney disease, according to results from a cohort study.
Autosomal dominant PKD registry may help assess disease burden in patients with CKD
The autosomal dominant polycystic kidney disease registry may help assess various aspects of disease burden on patients’ health-related quality of life, according to published research.
FDA grants orphan drug designation to AP303 for autosomal dominant PKD
The FDA has granted orphan drug designation to AP303 for the treatment of autosomal dominant polycystic kidney disease.
Outcomes reported by adults with autosomal dominant PKD predicted hospitalizations
Patient-reported outcome scores effectively predicted clinical and health-economic outcomes in adults with autosomal dominant polycystic kidney disease, a study found.
Older patients with autosomal dominant PKD may benefit from tolvaptan treatment
Older patients with autosomal dominant polycystic kidney disease experienced a slowed annual rate of GFR decline by 1.66 mL/min/1.73 m2 per year when taking tolvaptan treatment, according to data published in Kidney Medicine.
FDA grants orphan drug designation for Xorlo to treat autosomal dominant PKD
The FDA granted orphan drug designation for Xorlo, a drug from Xortx Therapeutics Inc. intended to treat autosomal dominant polycystic kidney disease, according to the press release.
FDA grants PXL770 orphan drug designation for autosomal-dominant polycystic kidney disease
The FDA has granted orphan drug designation to PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase activator designed by Poxel to treat autosomal-dominant polycystic kidney disease, according to a press release.
Researchers develop second building block for growing human kidneys
The journey to building an artificial human kidney with stem cells may be one step shorter with recent developments.
Challenges exist when translating research findings into clinical practice
Health care professionals find it challenging to interpret and translate research findings into clinical practice, specifically findings about autosomal dominant polycystic kidney disease.